205 related articles for article (PubMed ID: 16033845)
1. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient.
Nagata Y; Hanagiri T; Takenoyama M; Fukuyama T; Mizukami M; So T; Ichiki Y; Sugaya M; Sugio K; Yasumoto K
Clin Cancer Res; 2005 Jul; 11(14):5265-72. PubMed ID: 16033845
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma.
Fukuyama T; Hanagiri T; Takenoyama M; Ichiki Y; Mizukami M; So T; Sugaya M; So T; Sugio K; Yasumoto K
Cancer Res; 2006 May; 66(9):4922-8. PubMed ID: 16651449
[TBL] [Abstract][Full Text] [Related]
3. Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.
Kuroda K; Takenoyama M; Baba T; Shigematsu Y; Shiota H; Ichiki Y; Yasuda M; Uramoto H; Hanagiri T; Yasumoto K
Cancer Sci; 2010 Jan; 101(1):46-53. PubMed ID: 19799608
[TBL] [Abstract][Full Text] [Related]
4. Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression.
Baba T; Hanagiri T; Takenoyama M; Shiota H; Kuroda K; Shigematsu Y; Ichiki Y; Uramoto H; So T; Yasumoto K
Cancer Sci; 2010 Oct; 101(10):2115-20. PubMed ID: 20649604
[TBL] [Abstract][Full Text] [Related]
5. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.
So T; Takenoyama M; Mizukami M; Ichiki Y; Sugaya M; Hanagiri T; Sugio K; Yasumoto K
Cancer Res; 2005 Jul; 65(13):5945-52. PubMed ID: 15994973
[TBL] [Abstract][Full Text] [Related]
6. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma.
So T; Takenoyama M; Ichiki Y; Mizukami M; So T; Hanagiri T; Sugio K; Yasumoto K
Cancer; 2005 Jan; 103(1):200-8. PubMed ID: 15573370
[TBL] [Abstract][Full Text] [Related]
7. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.
Sugaya M; Takenoyama M; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Ichiki Y; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
Int J Cancer; 2007 Mar; 120(5):1055-62. PubMed ID: 17131342
[TBL] [Abstract][Full Text] [Related]
8. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
[TBL] [Abstract][Full Text] [Related]
9. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
10. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma.
Echchakir H; Mami-Chouaib F; Vergnon I; Baurain JF; Karanikas V; Chouaib S; Coulie PG
Cancer Res; 2001 May; 61(10):4078-83. PubMed ID: 11358829
[TBL] [Abstract][Full Text] [Related]
11. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
[TBL] [Abstract][Full Text] [Related]
12. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
[TBL] [Abstract][Full Text] [Related]
13. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.
Baba T; Hanagiri T; Ichiki Y; Kuroda K; Shigematsu Y; Mizukami M; Sugaya M; Takenoyama M; Sugio K; Yasumoto K
Cancer Sci; 2007 Nov; 98(11):1795-802. PubMed ID: 17725806
[TBL] [Abstract][Full Text] [Related]
14. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
[TBL] [Abstract][Full Text] [Related]
15. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
[TBL] [Abstract][Full Text] [Related]
16. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.
Hogan KT; Eisinger DP; Cupp SB; Lekstrom KJ; Deacon DD; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL; Ross MM
Cancer Res; 1998 Nov; 58(22):5144-50. PubMed ID: 9823325
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
18. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
19. Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous cancer cells.
Hirohashi Y; Torigoe T; Hirai I; Tamura Y; Nakatsugawa M; Inoue Y; Kanaseki T; Kamiguchi K; Ikeda H; Sasaki A; Yamanaka N; Sato N
Exp Mol Pathol; 2010 Feb; 88(1):128-32. PubMed ID: 19818766
[TBL] [Abstract][Full Text] [Related]
20. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
